BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has begun shipping MONOVISC™ to Europe. MONOVISC is a single-injection viscosupplement therapy approved in the European Economic Area for treatment of osteoarthritis symptoms in all synovial joints. Other viscosupplements are indicated for specific joints, and may require up to five injections for the same treatment.
